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Abstract 
Antipsychotic medications are effective in the treatment of acute psychosis, irrespective of cause, chronic 
psychotic disorders, and other psychiatric and non-psychiatric conditions. They are categorized into 
first-generation antipsychotics (FGAs), also known as “typical” antipsychotics, and second-generation 
antipsychotics (SGAs), or otherwise known as “atypical” antipsychotics. This review article summarizes 
both typical and atypical antipsychotics, as well as, examines the mechanism and propensity of these agents 
to prolong the QTc interval.      
Keywords: Chlorpromazine, Clozapine, Antipsychotic History, Typical and Atypical Antipsychotics, 
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1. Background: History of antipsychotic drug development (Shen, 1999) 
The history of antipsychotics in treating psychotic disorders is based on chance findings after 
chlorpromazine was administered to patients for its potential anesthetic effects during surgeries in 1951 
(Laborit et al., 1952). Shortly thereafter, researchers discovered their antipsychotic activity following their 
use in psychiatric patients (Ban, 2007), and soon several first generation or typical antipsychotics were 
introduced to the world market (Ban et al., 1998). It was not until late the 1980s, that we were introduced to 
"atypical" antipsychotic drugs, with the approval of clozapine. Clozapine was found to be more effective in 
treating schizophrenia than FGAs, and carried significantly less risk of developing extrapyramidal 
symptoms (EPS) and tardive dyskinesia (TD) (Kane et al., 1988). However, other side effects, specifically 
agranulocytosis, a serious, life-threatening condition, limited its use (Jose et al., 1993; Alvir et al., 1993). 
Therefore, development continued in order to discover safer atypical antipsychotics, and they have now 
replaced FGAs as standard of care for schizophrenia. 
2. Introduction and Indications 
Schizophrenia is a psychiatric disorder involving chronic or recurrent psychosis that typically impairs social 
and occupational functioning. Schizophrenia is believed to occur due to excess dopamine in the mesolimbic 
pathway. Excess dopamine causes a deficit in sensory gating, and often patients become hyper vigilant and 
respond to extraneous stimuli that others typically ignore. Positive symptoms associated with schizophrenia 
include hallucinations or delusions, disorganized speech, negative symptoms such as a flat affect or poverty 
of speech, and impairments in cognition including attention, memory and executive functions. 
Schizophrenia is diagnosed based on the presence of such symptoms, along with the presence of social or 
Journal of Pharmacy and Alternative Medicine    www.iiste.org 
ISSN 2222-5668 (Paper) ISSN 2222-4807 (Online)  
Vol. 2, No. 4, 2013 
 
4 
occupational dysfunction for at least six months, in the absence of another diagnosis that would better 
account for the patient’s symptoms. Differential diagnoses include, but are not limited to, medications, such 
as corticosteroids, anticholinergics, and dopamine agonists, infection, tumor, endocrine disorder (elevated 
thyroid function), temporal lobe epilepsy, and illicit drug use, such as cocaine, alcohol, amphetamines, 
and/or hallucinogens. During adolescence, one may experience prodrome symptoms, such as having 
difficulty relating to others or being socially awkward.  The onset of schizophrenia typically occurs in the 
third or fourth decades of life, with earlier onset in males versus females. It is a chronic disease, with 
episodes of remission and relapse, with residual symptoms in between relapses. 
 
 
 
 
 
 
 
 
 
 
Schizophrenia is categorized into five subtypes, catatonic, disorganized, paranoid, undifferentiated, and 
residual. Catatonic schizophrenia includes episodes of behavior at extreme opposite ends of the behavioral 
spectrum. For instance, one may be in coma-like daze, unable to speak, move or respond; they are resistant 
to movement and are in a ‘catatonic stupor’. On the other end of the spectrum, they may talk and behave in 
a bizarre, hyperactive way. Catatonic episodes may last for a month or longer without treatment, but this 
type of schizophrenia is rare now that we are able to utilize antipsychotics. Disorganized schizophrenia is 
considered a more severe type of schizophrenia, in which ones’ thoughts, speech and behavior are 
inappropriate and don't make sense. These patients may have difficulty performing routine daily activities, 
such as bathing themselves, and cooking a meal. Paranoid schizophrenia is the most common type of 
schizophrenia, characterized by relatively stable, often paranoid, delusions, usually accompanied by 
hallucinations, particularly of the auditory variety, and perceptual disturbances. Patients with paranoid 
schizophrenia may be more capable in performing functions of daily living than other forms of 
schizophrenia. However, this form of schizophrenia can lead to many complications, including suicidal 
behavior. Residual schizophrenia is characterized by a past history of at least one episode of schizophrenia, 
but the person currently has no "positive" symptoms (e.g. delusions, hallucinations, disorganized speech, or 
behavior). Undifferentiated schizophrenia is characterized by some symptoms seen in all of the above types, 
but not enough of any one of them to define it as another particular type of schizophrenia (DSM-IV-TR). 
The cardinal goals of treatment with antipsychotic medications are to reduce the frequency and severity of 
psychotic exacerbations, ameliorate symptoms, and improve functional capacity and quality of life. 
Schizophrenia is categorized into five subtypes, catatonic, disorganized, paranoid, undifferentiated, and 
residual. Catatonic schizophrenia includes episodes of behavior at extreme opposite ends of the behavioral 
spectrum. For instance, one may be in coma-like daze, unable to speak, move or respond; they are resistant 
to movement and are in a ‘catatonic stupor’. On the other end of the spectrum, they may talk and behave in 
a bizarre, hyperactive way. Catatonic episodes may last for a month or longer without treatment, but this 
type of schizophrenia is rare now that we are able to utilize antipsychotics. Disorganized schizophrenia is 
considered a more severe type of schizophrenia, in which ones’ thoughts, speech and behavior are 
inappropriate and don't make sense. These patients may have difficulty performing routine daily activities, 
such as bathing themselves, and cooking a meal. Paranoid schizophrenia is the most common type of 
schizophrenia, characterized by relatively stable, often paranoid, delusions, usually accompanied by 
hallucinations, particularly of the auditory variety, and perceptual disturbances. Patients with paranoid 
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schizophrenia may be more capable in performing functions of daily living than other forms of 
schizophrenia. However, this form of schizophrenia can lead to many complications, including suicidal 
behavior. Residual schizophrenia is characterized by a past history of at least one episode of schizophrenia, 
but the person currently has no "positive" symptoms (e.g. delusions, hallucinations, disorganized speech, or 
behavior). Undifferentiated schizophrenia is characterized by some symptoms seen in all of the above types, 
but not enough of any one of them to define it as another particular type of schizophrenia (DSM-IV-TR). 
The cardinal goals of treatment with antipsychotic medications are to reduce the frequency and severity of 
psychotic exacerbations, ameliorate symptoms, and improve functional capacity and quality of life 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. First-generation antipsychotics (FGAs) 
First-generation antipsychotics (FGAs), also known as neuroleptics, major tranquilizers, or “typical” 
antipsychotics, are effective in treating positive symptoms but are ineffective in treating negative or 
cognitive symptoms associated with schizophrenia. FGAs work by antagonizing dopamine at D2 receptors 
throughout the brain, and binding is highly correlated with clinical potency (Seeman, 2002) and side effects 
such as movement disorders and elevated prolactin levels. Besides their activity at D2 receptors, each FGA 
has a distinct effect on alpha adrenergic (α) and muscarinic acetylcholine receptors (mAChRs or 
metabotropic), leading to additional side effects associated with these agents. FGAs are lipophilic, highly 
protein and tissue-bound compounds with large volumes of distribution and fairly long half-lives. They 
undergo extensive metabolism via cytochrome P450 (CYP) enzymes, and several agents have active 
metabolites. Therefore, drug-drug interactions can occur with the co-administration with potent cytochrome 
P450 (CYP) inhibitors or inducers. Most FGAs are available in oral formulations. However, several are also 
available as injectable, intramuscular (IM) formulations, which are useful in the treatment of psychotic 
agitation. In addition, long-acting decanoate formulations of haloperidol and fluphenazine can be 
administered via intramuscular injection one to two times per month for those patients who are 
Table 1. Schizophrenia Subtype 
Type Description 
Catatonic  Episodes of behavior at extreme 
opposite ends of the behavioral 
spectrum  
 Rare now that can treat schizophrenia 
Disorganized  Thoughts, speech and behavior that 
are inappropriate and don't make 
sense 
Paranoid  Most common form 
 Delusions or hallucinations (typically 
auditory) 
 Least functional impairments with the 
best prognosis. However, has the 
highest suicide 
Residual  History of at least one episode of 
schizophrenia, but no current positive 
symptoms 
Undifferentiated  No defined symptoms to place in one 
particular subtype listed above  
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non-adherent with daily oral dosing. First generation antipsychotics have traditionally been classified by 
their chemical structure (eg, phenothiazines, butyrophenones, thioxanthenes).  
 
 
 
 
 
 
 
 
 
Figure 2: FGA receptor binding 
However, differences between chemical classes do not translate into differences in drug efficacy, side 
effects, or types of patients that respond. For the majority, FGAs have comparable efficacy in the treatment 
of psychosis. What they differ in is their side effect profile, which is captured in the classification of these 
agents as either high- or low-potency. High potency antipsychotics tend to be less histaminergic, alpha 
adrenergic and anticholinergic. Meaning they are less sedating (histaminergic), they do not cause as much 
blurred vision, urinary retention, dry mouth, or constipation (anticholinergic), or orthostatic hypotension 
(alpha adrenergic) when compared to low potency FGAs. High potency FGAs also carry a low to moderate 
risk of weight gain, but a higher risk of developing EPS and neuroleptic malignant syndrome (NMS). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: FGA classification by potency 
3.1 High potency FGAs 
Haloperidol (Haldol®) is the most extensively studied and remains the most widely used FGA. It is 
available as an oral tablet, solution or short-acting injectable formulation for IM and intravenous (IV) use.  
It is also available as a long acting decanoate depot injection given intramuscularly at a dose of 25 to 100 
mg every 4 weeks. Although, haloperidol is absorbed orally, its bioavailability is reduced (60%) because of 
extensive first-pass hepatic metabolism. It is cleared by cytochrome P450 isoenzymes CYP3A4 and 
CYP2D6, and glucuronidation, with a half-life of about 20 hours (oral formulation) (Kudo and Ishizaki, 
2002). It can interact with potent inhibitors or inducers of these cytochrome P450 isoenzymes, with notable 
elevated levels when administered with fluoxetine, paroxetine, and bupropion, and decreased levels with 
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carbamazepine. Many times, the interactions can be managed with dose adjustments. Drug interactions with 
medications that can also prolong the QTc interval should be taken into consideration. Given its 
classification as a high potency FGA, haloperidol carries an increased risk of developing EPS. As a way to 
prevent the development of EPS, the dose of oral haloperidol has decreased over the years, and is currently 
being used at doses of 10 to 20 mg/day. Doses of IM injection, for the treatment of agitation associated with 
psychosis, typically ranges from 2 to 10 mg, given as often as every 30 minutes with effects peaking at 20 
minutes after administration.  
Fluphenazine (Prolixin®) is a phenothiazine piperazine that is clinically comparable to haloperidol in most 
regards, with similar efficacy, potency, routes of administration, dosing, and side effects.  It is available as 
oral tablets, solution or IM injection and the typical dose range is 2 to 20 mg/day. Like haloperidol, it also 
comes in a long-acting decanoate injection (IM) given at a dose of 6.25 to 50mg every 2 weeks.  Of all 
depot injections though, fluphenazine is most likely to “dump”, or release the drug into the body all at once. 
The half-life of oral fluphenazine has been reported to be as high as 33 hours (Midha et al., 1983), and the 
half-life of fluphenazine decanoate is around 14 days. Fluphenazine is metabolized primarily in the liver via 
cytochrome P450 isoenzyme CYP2D6. 
3.2 Intermediate potency FGAs  
Intermediate potency FGAs tend to have a more moderate side effect profile when compared to high 
potency FGAs. Thiothixene (Navane®), a thioxanthene compound, is only available as an oral capsule, 
dosed 4 to 40 mg administered at least twice daily. Efficacy, dosing, and side effects are indistinguishable 
from haloperidol. Trifluoperazine (Stelazine®) is a phenothiazine piperazine, available as an oral tablet, 
dosed 4 to 40 mg administered twice daily. It may also be used for non-psychotic anxiety, at lower doses, 
such as 1-2 mg twice daily. Perphenazine (Trilafon®), a piperazinyl phenothiazine, is available as an oral 
tablet dosed 10 to 64 mg administered twice daily. It is also available as combination tablet with 
amitriptyline, approved for use in depression, anxiety, and agitation. Perphenazine is metabolized via 
multiple metabolic pathways, thus leading to potentially fewer drug-drug interactions. Another clinical 
advantage, perphenazine has a lower rate of EPS compared to haloperidol, and a comparable rate to 
risperidone, a second generation antipsychotic (Coley et al., 1999). Loxapine (Loxitane®), a 
dibenzoxazepine, is available as an oral capsule dosed 10 to 80 mg daily, divided into at least two daily 
doses. The efficacy and side effect profile of loxapine is similar to haloperidol with one exception, in that it 
may cause less weight gain.  
3.3 Low potency FGAs 
Chlorpromazine (Thorazine®), a phenothiazine, was the first antipsychotic on the market in the 1950s. 
Newer antipsychotics have since replaced chlorpromazine due to its side effect profile, and newer 
antiemetics that have better efficacy and fewer side effects have superseded chlorpromazine’s use in this 
area as well. Chlorpromazine is available as an oral tablet and solution and an IM injection, dosed 100 to 
800 mg/day. Single injectable doses for acute agitation are usually 50 to 200 mg. Thioridazine (Mellaril®), 
a piperidine phenothiazine, is available as an oral tablet dosed 100 to 800 mg/day. A unique adverse effect 
associated with thioridazine is retinitis pigmentosa when used at high doses. Also, thioridazine is associated 
with a higher risk of QT prolongation and lethal torsade de pointes (TdP) when compared to other 
antipsychotics. As a result, it has been discontinued in some countries, and is reserved only after failed 
trials of other antipsychotics, in the U.S. 
4. Second-generation antipsychotics (SGAs) 
Second-generation antipsychotics (SGAs), also known as “atypical” antipsychotics, are similar to FGAs in 
that they also work by blocking D2 receptors. However, SGAs differ from FGAs in that serotonin 5HT2 
receptor binding can exceed their affinity for dopamine D2 receptors. Furthermore, aripiprazole is unique, 
in that it also acts as a partial D2 agonist. The differences in affinity for other neurotransmitter receptors 
help explain some of the differences in SGAs’ side effect profile and the mood and cognitive benefits one 
may get with their use. However, one author believes that SGAs’ low-affinity and fast dissociation from the 
dopamine D2 receptor, along with the administration in doses that provide adequate levels of dopamine D2 
receptor blockade lead to their “atypicality”, rather than their actions on neurotransmitter receptors besides 
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D2 (Kapur and Remington, 2001). In general, SGAs have minimal effect on serum prolactin and carry a 
lower risk of EPS and tardive dyskinesia compared to FGAs. However, SGAs may cause higher rates of 
weight gain and metabolic side effects, varying in their degree depending on the agent. Although, SGAs 
have replaced FGAs as the standard of care, the question of whether they are more effective than FGAs 
remains uncertain. In large-scale studies, such as the Clinical Antipsychotic Trials of Intervention 
Effectiveness (CATIE) (Lieberman et al., 2005) and the European First Episode Schizophrenia Trial (Kahn 
et al., 2008), they found that SGAs may be no more effective than FGAs. In any case, it is known that 
SGAs are associated with a better safety profile, possibly leading to better adherence to treatment, and is an 
option for those patients who are labeled as treatment-refractory to FGAs. As far as comparing efficacy 
between SGAs, all have similar efficacy, with the exception of clozapine, which has an advantage in 
treating refractory schizophrenia. 
Table 2: SGA side effect profiles 
 
 
All SGAs are available as oral tablets or capsules, and like FGAs, many are available as injectable, IM 
formulations, useful in the treatment of psychotic agitation. In addition, long-acting decanoate formulations 
of risperidone, paliperidone, aripiprazole, and olanzapine are available. 
Table 3: SGA dosing and formulations 
 
 
 
 
 
 
 
 
 
 
T – tablet; RTD – rapid disintegrated tablet; C – capsule; SOL – oral solution; IM – intramuscular injection; 
IR – immediate release; ER – extended release; SL - sublingual 
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5. QT Prolongation 
The QT interval is the length of time from the start of the Q wave to the end of the T wave, and represents 
the time it takes for ventricular depolarization and repolarization. It is inversely proportional to heart rate, 
meaning the interval is shortened at faster heart rates and lengthened at slower heart rates. Because of this, 
the interval duration is usually corrected for heart rate and referred to as the QTc interval. Normal QTc 
values are not universally established due to multiple variables that affect its measurement such as gender, 
time of day, diet, heart rate, and lead selection when measuring. However, an interval below 440ms is 
generally considered to be normal. It is when the interval lengthens, that the risk of torsade de pointes 
(TdP), a polymorphic ventricular tachycardia, increases. Generally, the normal upper limit for QTc is 
considered to be 450ms for men and 460ms for women, and a QTc interval of > 500 ms is considered to be 
a substantial risk factor for TdP (Moss and Robinson, 1992). Also, clinicians should be concerned with a 
greater than 25% increase in the QTc interval from baseline.  
Schizophrenia and other psychiatric disorders are associated with an increased risk of cardiovascular 
disease and higher baseline QTc intervals relative to the general population. In addition, there are 
well-established concerns over QTc prolongation and the development of life-threatening arrhythmias, with 
the use of antipsychotic drugs. It is important for clinicians to recognize the risks associated with QTc 
prolongation in order to prevent arrhythmias, especially those caused by drugs including certain antibiotics, 
antiarrhythmics, selective serotonin receptor inhibitors (SSRI), and other medications such as methadone. 
Other risk factors for QTc prolongation include but are not limited to age above  65 years old, female 
gender, congenital long QT syndrome (LQTS), personal or family history of LQTS,  cardiovascular 
disease, and electrolyte disturbances (i.e. hypokalemia, hypomagnesemia, hypocalcaemia). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: QTc prolongation MOA 
The QT prolonging tendency of antipsychotics is based on the capacity to inhibit the cardiac delayed 
potassium rectifier channel (IKr) (Sanguinetti et al., 1995; Yang and Roden, 1996). The inhibition of IKr 
extends the repolarization process of the ventricles of the heart, displayed as a prolongation of the QT 
interval on an electrocardiogram (ECG). This blockade may cause enough prolongation to generate extra 
potentials that may lead to premature ventricular beats capable of triggering TdP and sudden cardiac death 
(SCD). 
Crumb and colleagues studied the effects of haloperidol, olanzapine, risperidone, thioridazine, and 
ziprasidone on several ionic currents that contribute to changes in the action potential in cardiac tissue. 
They found that the blockade of the hERG, a K+ channel gene, ion channel is the likely mechanism for the 
prolongation of the QT interval. In addition they found relatively modest increases in QTc prolongation 
during treatment with olanzapine, risperidone, and haloperidol (1.7, 3.6, and 7.1 msec, respectively), and 
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more pronounced increases for ziprasidone and thioridazine (15.9 and 30.1 msec, respectively) (Crumb W, 
et al. 2006).  
As a class, typical antipyschotics seem to prolong the QTc interval more so than atypical antipsychotics, 
and in general, low potency typical antipsychotics are thought to carry a greater risk than high-potency 
agents. This risk is thought to be dose related. The best available data comes from a randomized, 
prospective study, that Pfizer did at the FDA’s request, comparing the effects of six antipsychotics on the 
QTc interval at and around the time of estimated peak plasma/serum concentrations in medically healthy 
individuals with psychotic disorders (Harrigan EP, et al 2004).  Thioridazine (at a moderate dose of 300 
mg/day) showed the greatest prolongation of the QTc compared with ziprasidone (160 mg/d), risperidone 
(up to 16 mg/d), olanzapine (20 mg/d), quetiapine (750 mg/d), or haloperidol (15 mg/d).  In addition, this 
study found that inhibition of the major CYP450 pathways for each antipsychotic studied did not result in 
large increases in drug levels (except for quetiapine) or augmentation of QTc prolongation. The authors 
suggested the reason being that alternative metabolic pathways might share responsibility for drug 
clearance for these agents. 
Table 4: Effects of antipsychotics on the QTc interval 
 
 
 
 
 
 
 
 
 
 
Haloperidol, despite being a high-potency agent, has been linked in case reports to QTc prolongation and 
TdP, though the frequency and magnitude of QTc prolongation is thought to be substantially less than with 
thioridazine and similar to that with many atypical antipsychotics. In this study, oral haloperidol prolonged 
the QTc interval by less than 5 msec, not reflective of its ability to cause QTc prolongation and TdP seen in 
the literature.  When used for in-hospital agitation, intravenous (IV) haloperidol produced a 
dose-dependent increase in the risk of a QTc > 500 msec and the risk of TdP (Sharma et al., 1998).  The 
higher risk of QTc prolongation and TdP with IV haloperidol may be explained in part by the fact that it is 
used relatively frequently in medically ill individuals, who are likely at higher risk for QTc prolongation 
and TdP to begin with.  
Although atypical antipsychotics appear to have some risk of QTc interval prolongation, these agents have 
only been implicated in the development of TdP in rare case reports and FDA adverse event reports. In 
healthy volunteers, ziprasidone seems to cause the greatest mean QTc prolongation when compared with 
other SGAs, with a plateau effect at approximately 20msec. Quetiapine also seems to cause a 
dose-dependent, moderate increase in the QTc interval, by an average of 15–20 msec (Anonymous. Study 
054, 2000). SGAs such as clozapine, olanzapine, aripiprazole, and paliperidone seem to have the least 
potential for significant QTc prolongation (Li et al., 2010).  
6. Conclusion 
Prevention of QTc prolongation with the use of antipsychotics is hard to predict, and not all patients will 
experience QTc prolongation. Additionally, it is difficult to assess how much of an increase in the QTc 
interval warrants action. Despite the known association between the prolongation of the QTc interval and 
dysrhythmias, researchers recognize that this link and the risk of clinical events is poorly understood. What 
is understood, though, is the importance to assess risk factors for QTc prolongation, and to obtain a baseline 
Journal of Pharmacy and Alternative Medicine    www.iiste.org 
ISSN 2222-5668 (Paper) ISSN 2222-4807 (Online)  
Vol. 2, No. 4, 2013 
 
11 
QTc before initiating any antipsychotic agent.  Also, if, for a given indication, different drugs are available, 
clinicians should consider the QTc prolongation tendency of each agent when making their choice. After 
obtaining a baseline QTc before initiation, patients should have repeated ECGs 7 days after start of therapy 
and when any dose changes are made. Clinicians should use their clinical judgment when determining 
actions taken if QTc prolongation occurs. Generally, if the QTc > 450 msec for a drug or combination of 
drugs, the dose should be decreased or the drug be replaced by another not known to or has less propensity 
to prolong the QTc interval. In the case of a QTc > 500 msec for a drug or combination of drugs, the drug 
should be replaced. In both cases, repeat ECGs should be performed after action has been taken, and the 
patient’s serum electrolyte levels should be monitored carefully. 
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